NATERA INC (NTRA) Stock Fundamental Analysis
USA - NASDAQ:NTRA - US6323071042 - Common Stock
204.28 USD
+3.61 (+1.8%)
204.28 USD
0 (0%)
Taking everything into account, NTRA scores 4 out of 10 in our fundamental rating. NTRA was compared to 533 industry peers in the Biotechnology industry. NTRA has a great financial health rating, but its profitability evaluates not so good. NTRA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NTRA had negative earnings in the past year.
NTRA had a positive operating cash flow in the past year.
In the past 5 years NTRA always reported negative net income.
In the past 5 years NTRA reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of NTRA (-14.41%) is better than 81.17% of its industry peers.
NTRA has a better Return On Equity (-20.32%) than 83.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.41% | ||
| ROE | -20.32% | ||
| ROIC | N/A |
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NTRA's Gross Margin of 62.86% is fine compared to the rest of the industry. NTRA outperforms 79.28% of its industry peers.
In the last couple of years the Gross Margin of NTRA has grown nicely.
The Profit Margin and Operating Margin are not available for NTRA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
2. Health
2.1 Basic Checks
NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NTRA has been increased compared to 1 year ago.
NTRA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NTRA has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 32.03 indicates that NTRA is not in any danger for bankruptcy at the moment.
NTRA's Altman-Z score of 32.03 is amongst the best of the industry. NTRA outperforms 94.73% of its industry peers.
NTRA has a debt to FCF ratio of 0.77. This is a very positive value and a sign of high solvency as it would only need 0.77 years to pay back of all of its debts.
NTRA's Debt to FCF ratio of 0.77 is amongst the best of the industry. NTRA outperforms 94.16% of its industry peers.
NTRA has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NTRA (0.06) is worse than 61.77% of its industry peers.
Even though the debt/equity ratio score it not favorable for NTRA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.77 | ||
| Altman-Z | 32.03 |
ROIC/WACCN/A
WACC8.73%
2.3 Liquidity
NTRA has a Current Ratio of 3.72. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NTRA (3.72) is comparable to the rest of the industry.
NTRA has a Quick Ratio of 3.58. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
NTRA has a Quick ratio (3.58) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.58 |
3. Growth
3.1 Past
The earnings per share for NTRA have decreased strongly by -30.11% in the last year.
Looking at the last year, NTRA shows a very strong growth in Revenue. The Revenue has grown by 38.17%.
The Revenue has been growing by 41.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.15%
Revenue 1Y (TTM)38.17%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%34.66%
3.2 Future
NTRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.38% yearly.
NTRA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.62% yearly.
EPS Next Y-32.78%
EPS Next 2Y7.14%
EPS Next 3Y29.95%
EPS Next 5Y26.38%
Revenue Next Year26.21%
Revenue Next 2Y20.7%
Revenue Next 3Y19.53%
Revenue Next 5Y16.62%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
NTRA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NTRA is cheaper than 90.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 268.15 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NTRA's earnings are expected to grow with 29.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.14%
EPS Next 3Y29.95%
5. Dividend
5.1 Amount
NTRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
204.28
+3.61 (+1.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93.57%
Inst Owner Change9.97%
Ins Owners3.13%
Ins Owner Change-4.78%
Market Cap28.04B
Revenue(TTM)2.12B
Net Income(TTM)-253.24M
Analysts84.44
Price Target198.71 (-2.73%)
Short Float %2.92%
Short Ratio3.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.64%
Min EPS beat(2)-17.78%
Max EPS beat(2)23.06%
EPS beat(4)2
Avg EPS beat(4)14.54%
Min EPS beat(4)-17.78%
Max EPS beat(4)55.66%
EPS beat(8)6
Avg EPS beat(8)19.24%
EPS beat(12)9
Avg EPS beat(12)15.23%
EPS beat(16)11
Avg EPS beat(16)9.5%
Revenue beat(2)2
Avg Revenue beat(2)11.38%
Min Revenue beat(2)10.25%
Max Revenue beat(2)12.51%
Revenue beat(4)4
Avg Revenue beat(4)12.74%
Min Revenue beat(4)8.92%
Max Revenue beat(4)19.28%
Revenue beat(8)8
Avg Revenue beat(8)11.42%
Revenue beat(12)10
Avg Revenue beat(12)8.34%
Revenue beat(16)14
Avg Revenue beat(16)6.87%
PT rev (1m)0.38%
PT rev (3m)1.14%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)10.46%
EPS NY rev (1m)-2.9%
EPS NY rev (3m)9.45%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)1.14%
Revenue NY rev (3m)4.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.27 | ||
| P/FCF | 268.15 | ||
| P/OCF | 150.17 | ||
| P/B | 22.5 | ||
| P/tB | 22.5 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.29
EYN/A
EPS(NY)-1.3
Fwd EYN/A
FCF(TTM)0.76
FCFY0.37%
OCF(TTM)1.36
OCFY0.67%
SpS14.31
BVpS9.08
TBVpS9.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.41% | ||
| ROE | -20.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.86% | ||
| FCFM | 5.32% |
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
F-Score6
Asset Turnover1.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.77 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 234.12% | ||
| Cap/Sales | 4.18% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.72 | ||
| Quick Ratio | 3.58 | ||
| Altman-Z | 32.03 |
F-Score6
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)232.23%
Cap/Depr(5y)273.02%
Cap/Sales(3y)4.66%
Cap/Sales(5y)5.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.15%
EPS Next Y-32.78%
EPS Next 2Y7.14%
EPS Next 3Y29.95%
EPS Next 5Y26.38%
Revenue 1Y (TTM)38.17%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%34.66%
Revenue Next Year26.21%
Revenue Next 2Y20.7%
Revenue Next 3Y19.53%
Revenue Next 5Y16.62%
EBIT growth 1Y6.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.74%
EBIT Next 3Y44.52%
EBIT Next 5Y27.11%
FCF growth 1Y127%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y154.49%
OCF growth 3YN/A
OCF growth 5YN/A
NATERA INC / NTRA FAQ
What is the ChartMill fundamental rating of NATERA INC (NTRA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to NTRA.
Can you provide the valuation status for NATERA INC?
ChartMill assigns a valuation rating of 2 / 10 to NATERA INC (NTRA). This can be considered as Overvalued.
How profitable is NATERA INC (NTRA) stock?
NATERA INC (NTRA) has a profitability rating of 3 / 10.